Conflict of Interest Statement
Thomas
Marla C. Dubinsky: consultancy fees and research grants from Pfizer Inc. Alessandro Armuzzi: consultancy fees from AbbVie, Allergan, Amgen, Arena, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen, MSD, Mylan, Pfizer Inc, Roche, Samsung Bioepis, Sandoz, and Takeda; lecturing fees from AbbVie, Amgen, Biogen, Bristol Myers Squibb, Chiesi, Ferring Pharmaceuticals, Gilead Sciences, Janssen, MSD, Mitsubishi Tanabe, Nikkiso, Novartis, Pfizer Inc, Roche, Samsung Bioepis, Sandoz, Takeda, and TiGenix; research grants from MSD, Pfizer Inc, and Takeda. Krisztina B. Gecse: research support from Celltrion, Galapagos, and Pfizer Inc; and speakers' honoraria and/or consulting fees from AbbVie, Arena Pharmaceuticals, Celltrion, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Immunic Therapeutics, Janssen, Novartis, Pfizer Inc, Samsung Bioepis, Takeda, and Tillotts. Thomas Ullman: no conflicts of interest to disclose. Andrew G. Bushmakin, Marco DiBonaventura, Joseph C. Cappelleri, Susan B. Connelly, John C. Woolcott, and Leonardo Salese: employees and stockholders of Pfizer Inc.